MRNA 10-Q: SEC filing
Moderna, Inc.
Filed with the SEC on · accession 0001682852-26-000197
MRNA filed a 10-Q (quarterly report) with the SEC on Nov 6, 2026. Moderna, Inc. filed a Form 10-Q quarterly report for the period ended September 30, 2026, accompanied by the standard Sarbanes-Oxley Section 302 certification from CEO Stéphane Bancel. The stock moved +5.3% by the first close after the filing.
Summary of the filing
Moderna, Inc. filed a Form 10-Q quarterly report for the period ended September 30, 2026, accompanied by the standard Sarbanes-Oxley Section 302 certification from CEO Stéphane Bancel. The certification confirms the accuracy of the financial statements and the effectiveness of disclosure controls and internal control over financial reporting.
Key details
How MRNA stock reacted
Close before
$241.46
Nov 5, 2026
First close after
+5.27%
$254.19
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for MRNA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MRNA?
Click hereFrequently asked questions
What did MRNA file with the SEC on Nov 6, 2026?
MRNA filed a 10-Q (SEC filing). Moderna, Inc. filed a Form 10-Q quarterly report for the period ended September 30, 2026, accompanied by the standard Sarbanes-Oxley Section 302 certification from CEO Stéphane Bancel. The certification confirms the accuracy of the financial statements and the effectiveness of disclosure controls and internal control over financial reporting.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did MRNA stock react to this filing?
MRNA closed at $241.46 before the filing and $254.19 on Nov 6, 2026 (+5.27%).
Other MRNA SEC filings
- 8-K · Guidance raiseNov 6, 2026
- SCHEDULE 13G/A · SEC filingNov 5, 2026
- 8-K · Executive departureSep 30, 2026
- 8-K · Material agreementSep 1, 2026
- SCHEDULE 13G · SEC filingAug 12, 2026
- 10-Q · SEC filingJul 31, 2026
- 8-K · Guidance raiseJul 31, 2026
- 8-K · Board changeJul 8, 2026
- 144 · Insider sale plannedJun 18, 2026
- 144 · Insider sale plannedJun 15, 2026
Get alerts when MRNA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days